Role of percent positive biopsies and endorectal coil MRI in predicting prognosis in intermediate-risk prostate cancer patients

Cancer Journal from Scientific American

Volumn 2, Issue 6, 1996, Pages 343-350

  D'Amico, Anthony V ^a   Whittington, Richard ^b   Malkowicz, S Bruce ^b   Schultz, Delray ^c   Schnall, Mitch ^b   Tomaszewski, John E ^b   Wein, Alan ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c University of Miliersville   (United States)

Author keywords

Magnetic resonance imaging; Prostate cancer; Prostate specific antigen; Staging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BIOPSY; BLOOD; CANCER INVASION; CANCER STAGING; HORMONE SUBSTITUTION; HUMAN; INSTRUMENTATION; MALE; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR; PROSTATECTOMY; RADIOGRAPHY; RECTUM; RISK FACTOR; SEMINAL VESICLE; SENSITIVITY AND SPECIFICITY; STATISTICS;

BIOPSY; HORMONE REPLACEMENT THERAPY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECTUM; RISK FACTORS; SEMINAL VESICLES; SENSITIVITY AND SPECIFICITY;

EID: 2842536018     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Trapasso JG, DeKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152:1821.
2. Partin AW, Yoo J, Ballentine Carter H, Pearson JD, Epstein JI, Walsh PC. The use of prostate specific antigen, clinical stage, and gleason score to predict pathologic stage in men with prostate cancer. J Urol 1993;150:110.
3. D'Amico AV, Whittington R, Malkowicz SB et al. A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 1994;30:293.
4. Presti JC, Katsuto S, Hricak H, White S, Cher M, Carroll PR. Clinical parameters in the preoperative evaluation for extracapsular extension at radical prostatectomy [abstract]. J Urol 1995;801: 429A.
5. Narayan P, Gajendran V, Taylor SP et al. The role of transrectal ultrasound-guided biopsy based staging, preoperative prostate specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 1995;46:205.
6. Myrtle JF, Klimley PG, Ivor LP, Brun JF. Clinical utility of prostate-specific antigen (PSA) in the management of prostate cancer. In: Advanced Cancer Diagnosis, San Diego, CA: Hybritech, Inc., 1986.
7. Beahrs OH, Henson DE, Hutter RW, Kennedy BJ. American Joint Committee on Cancer Manual for Staging Cancer. 4th ed. Philadelphia: J.B. Lippincott, 1992.
8. Schnall MD, Lenkinski RE, Pollack HM, Imai Y, Kressel HY. Prostate: MR imaging with an endorectal surface coil. Radiology 1989;172:570.
9. Schiebler ML, Schnall M, Pollack HM et al. Current role of MR imaging in the staging of adenocarcinoma of the prostate. Radiology 1993;189:339.
10. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582.
11. D'Amico AV, Whittington R, Malkowicz SB et al. A multivariate analysis of clinical and pathological factors which predict for prostate-specific antigen failure after radical prostatectomy after prostate cancet. J Urol 1995;154:131.
12. Cox DR. Regression models and life tables. JR Stat Soc B34;1: 1972.
13. Carter HB, Coffey DS. Prostate cancer: the magnitude of the problem in the United States. In: A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. Coffey DS, Resnick MI, Dorr FA, Karr JP, eds. New York: Plenum Press, 1988;1-7.
14. Catalona WJ, Dresner SM. Nerve-sparing radical prostatectomy: extraprostatic tumor extension and preservation of erectile function. J Urol 1985;134:1149.
15. Eggleston JC, Walsh PC. Radical prostatectomy with preservation of sexual function: pathologic findings in the radical prostatectomy specimens. Urology 1985;134:1146.
16. Gibbons RP, Cole BS, Richardson RG.:Adjuvant radiotherapy following radical prostatectomy: results and complications. J Urol 1986;135:65.
17. Middleton RG, Smith Jr JS, Metzer RB Hamilton PE. Patient survival and local recurrence following radical prostatectomy for prostatic carcinoma. J Urol 1986;136:422.
18. Thompson I, Crawford ED, Miller G et al. Adjuvant radiotherapy following radical prostatectomy for pathologic stage C adenocarcinoma of the prostate: initial evaluation of toxiciry [abstract]. Proc Am Soc Clin Oncol 1992;212:663.
19. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994;151:1571.
20. Katz AE, Olsson CA, Raffo AJ et al. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 1994;43:765.
21. Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC et al. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology 1994;44:371.
22. Peller PA, Young DC, Marmaduke DP, Marsh WL, Badalament RA. Sextant prostate biopsies, a histopathologic correlation with radical prostatectomy specimens. Cancer 1995;75:530.